Skip to content
Search

Latest Stories

GSK to name new consumer healthcare venture 'Haleon' after spin-off in mid-2022

GlaxoSmithKline plc (GSK) announced on Tuesday (February 22) its new consumer healthcare venture with Pfizer will be called Haleon, confirming the business will be spun off in mid-2022.

The creation of Haleon follows a series of investments and strategic changes to GSK’s consumer health business over the last eight years, including integrations of the consumer product portfolios from Novartis and Pfizer. It is now a highly valuable and focused global business, generating annual sales of about £10 billion.


The name, Haleon is inspired by the merging of the words 'Hale', which means 'in good health' and Leon, which is associated with the word 'strength'.

After rejecting a buyout bid from Unilever, GSK is well positioned to deploy the new brand in more than 100 markets around the world.

Commenting on the announcement, Brian McNamara, chief executive officer designate, Haleon, said: “Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare.

“We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February.”

Emma Walmsley, chief executive officer, GSK, said: “Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders.”

The new brand will have a world-class portfolio including Sensodyne, Voltaren, Panadol and Centrum, the company stated.

With a strong demand in consumer healthcare sector, the business is set to grow sustainably, it added.

Haleon will be headquartered in Weybridge, UK, and is expected to attain a premium listing on the London Stock Exchange.

To inform investors and analysts about the overall strategy, capabilities and operations of Haleon, GSK will host a Consumer Healthcare Capital Markets Day for on Monday (February 28).

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
It is official: Opella is now a standalone company

Opella launches as an independent company to redefine the future of self-care.

Photo credit: gettyimages

Opella becomes standalone company as Sanofi-CD&R deal closes

Opella has officially become a standalone company, following the completion of Sanofi’s sale of a controlling 50.0% stake to private equity firm Clayton, Dubilier & Rice (CD&R).

Sanofi retains a significant shareholding with a 48.2% stake while Bpifrance holds the remaining 1.8% stake.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less